Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
An update from Arrowhead Pharmaceuticals ( (ARWR) ) is now available.
Arrowhead Pharmaceuticals appointed Douglas Ingram as a director on February 5, 2025, effective February 6, 2025, following an Investor Rights Agreement with Sarepta Therapeutics. Ingram, currently CEO of Sarepta, brings extensive industry experience from his previous leadership roles at Chase Pharmaceuticals and Allergan. His appointment coincides with Arrowhead’s strategic Collaboration Agreement with Sarepta for co-development and commercialization of various programs, marking a significant step in their partnership. This action impacts the company’s governance as Ingram is not considered an independent director under Nasdaq Listing Rules due to the Agreements.
More about Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals operates in the biopharmaceutical industry, focusing on developing medicines that treat intractable diseases by utilizing proprietary technologies to silence disease-causing genes.
YTD Price Performance: 4.22%
Average Trading Volume: 2,040,745
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $2.56B
See more insights into ARWR stock on TipRanks’ Stock Analysis page.
